(NASDAQ: ARTL) Artelo Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.05%.
Artelo Biosciences's earnings in 2026 is -$11,319,000.On average, 3 Wall Street analysts forecast ARTL's earnings for 2026 to be -$9,406,258, with the lowest ARTL earnings forecast at -$9,037,385, and the highest ARTL earnings forecast at -$9,682,913. On average, 3 Wall Street analysts forecast ARTL's earnings for 2027 to be -$5,047,260, with the lowest ARTL earnings forecast at -$4,849,329, and the highest ARTL earnings forecast at -$5,195,709.
In 2028, ARTL is forecast to generate $12,044,599 in earnings, with the lowest earnings forecast at $11,572,262 and the highest earnings forecast at $12,398,852.